The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 119, Issue 1, Pages 213-222
Publisher
Wiley
Online
2017-05-17
DOI
10.1002/jcb.26136
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting the tumor microenvironment as a potential therapeutic approach in colorectal cancer: Rational and progress
- (2017) Afsane Bahrami et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC).
- (2017) A. M. Gonzalez-Angulo et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies
- (2016) Amy Jo Chien et al. BREAST CANCER RESEARCH AND TREATMENT
- Systemic Therapy of Advanced/Metastatic Breast Cancer - Current Evidence and Future Concepts
- (2016) Cornelia Liedtke et al. Breast Care
- Abstract P3-07-41: Genomic alterations indicative of a luminal A subtype associate with clinical benefit to buparlisib and letrozole in endocrine-resistant ER+/HER2– metastatic breast cancer
- (2016) JM Balko et al. CANCER RESEARCH
- Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer
- (2016) Nathan Simon et al. JNCI-Journal of the National Cancer Institute
- Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain
- (2016) Xu Wan et al. Oncotarget
- Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer
- (2016) Nathan Simon et al. JNCI-Journal of the National Cancer Institute
- Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway
- (2015) Sharon T. Wilks BREAST
- Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results
- (2015) Ian Krop et al. CANCER RESEARCH
- Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population
- (2015) Neil E. Bhola et al. CANCER RESEARCH
- Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?
- (2015) Francesco Passiglia et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Biomarker Analysis in CLEOPATRA: Searching for a Sensitive Prognostic Factor in Breast Cancer
- (2015) Amir Avan et al. JOURNAL OF CLINICAL ONCOLOGY
- Intrinsic Subtypes,PIK3CAMutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial
- (2015) Katherine L. Pogue-Geile et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer
- (2015) Ian J. Majewski et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2
- (2015) Gabriel N. Hortobagyi NEOPLASIA
- Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
- (2014) C. Saura et al. CLINICAL CANCER RESEARCH
- Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
- (2014) Ingrid A. Mayer et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer
- (2014) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CAMutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer
- (2014) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus: side effect profile and management of toxicities in breast cancer
- (2013) Elisavet Paplomata et al. BREAST CANCER RESEARCH AND TREATMENT
- Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence ofde novoor acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor
- (2013) Paul Vilquin et al. INTERNATIONAL JOURNAL OF CANCER
- Dual Inhibition of PI3K and mTOR Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer
- (2013) Xiaosong Chen et al. MOLECULAR CANCER RESEARCH
- Targeting the PI3K-AKT-mTOR signaling network in cancer
- (2013) Khurum H. Khan et al. Chinese Journal of Cancer
- S5-1: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (pts) with HER2−Positive Breast Cancer (BC).
- (2012) L Gianni et al. CANCER RESEARCH
- Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells
- (2011) T. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer
- (2011) J. Baselga ONCOLOGIST
- Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
- (2010) Guy Jerusalem et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase II trial of a mammalian target of rapamycin inhibitor, temsirolimus, in patients with metastatic breast cancer.
- (2010) OM Hahn et al. CANCER RESEARCH
- Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab
- (2010) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
- (2010) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer
- (2010) L. S. Schwartzberg et al. ONCOLOGIST
- Dissecting the role of mTOR: Lessons from mTOR inhibitors
- (2009) Ryan J.O. Dowling et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer
- (2009) R. J. Crowder et al. CANCER RESEARCH
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Tenets of PTEN Tumor Suppression
- (2008) Leonardo Salmena et al. CELL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started